Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.

Guan J, Fransson S, Siaw JTT, Treis D, Van den Eynden J, Chand D, Umapathy G, Svenberg P, Ruuth K, Wessman S, Shamikh A, Jacobsson H, Gordon L, Stenman J, Larsson E, Svensson PJ, Hansson M, Martinsson T, Kogner P, Palmer RH, Hallberg B.

Cold Spring Harb Mol Case Stud. 2018 Jun 15. pii: mcs.a002550. doi: 10.1101/mcs.a002550. [Epub ahead of print]

2.

MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.

Umapathy G, Guan J, Gustafsson DE, Javanmardi N, Cervantes-Madrid D, Djos A, Martinsson T, Palmer RH, Hallberg B.

Sci Signal. 2017 Nov 28;10(507). pii: eaam7550. doi: 10.1126/scisignal.aam7550.

PMID:
29184034
3.

Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation.

Guan J, Yamazaki Y, Chand D, van Dijk JR, Ruuth K, Palmer RH, Hallberg B.

Cancers (Basel). 2017 Oct 30;9(11). pii: E149. doi: 10.3390/cancers9110149.

4.

Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.

Guan J, Wolfstetter G, Siaw J, Chand D, Hugosson F, Palmer RH, Hallberg B.

Oncotarget. 2017 Feb 14;8(7):11566-11578. doi: 10.18632/oncotarget.14141.

5.

The role of the ALK receptor in cancer biology.

Hallberg B, Palmer RH.

Ann Oncol. 2016 Sep;27 Suppl 3:iii4-iii15. doi: 10.1093/annonc/mdw301. Review.

PMID:
27573755
6.

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.

Guan J, Tucker ER, Wan H, Chand D, Danielson LS, Ruuth K, El Wakil A, Witek B, Jamin Y, Umapathy G, Robinson SP, Johnson TW, Smeal T, Martinsson T, Chesler L, Palmer RH, Hallberg B.

Dis Model Mech. 2016 Sep 1;9(9):941-52. doi: 10.1242/dmm.024448. Epub 2016 Jul 7.

7.

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.

Siaw JT, Wan H, Pfeifer K, Rivera VM, Guan J, Palmer RH, Hallberg B.

Oncotarget. 2016 May 17;7(20):29011-22. doi: 10.18632/oncotarget.8508.

8.

FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase.

Guan J, Umapathy G, Yamazaki Y, Wolfstetter G, Mendoza P, Pfeifer K, Mohammed A, Hugosson F, Zhang H, Hsu AW, Halenbeck R, Hallberg B, Palmer RH.

Elife. 2015 Sep 29;4:e09811. doi: 10.7554/eLife.09811.

9.

Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism.

Witek B, El Wakil A, Nord C, Ahlgren U, Eriksson M, Vernersson-Lindahl E, Helland Å, Alexeyev OA, Hallberg B, Palmer RH.

PLoS One. 2015 May 8;10(5):e0123542. doi: 10.1371/journal.pone.0123542. eCollection 2015.

10.

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.

Umapathy G, El Wakil A, Witek B, Chesler L, Danielson L, Deng X, Gray NS, Johansson M, Kvarnbrink S, Ruuth K, Schönherr C, Palmer RH, Hallberg B.

Sci Signal. 2014 Oct 28;7(349):ra102. doi: 10.1126/scisignal.2005470.

PMID:
25351247
11.

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

Fransson S, Hansson M, Ruuth K, Djos A, Berbegall A, Javanmardi N, Abrahamsson J, Palmer RH, Noguera R, Hallberg B, Kogner P, Martinsson T.

Genes Chromosomes Cancer. 2015 Feb;54(2):99-109. doi: 10.1002/gcc.22223. Epub 2014 Sep 23.

PMID:
25251827
12.

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Hallberg B, Palmer RH.

Nat Rev Cancer. 2013 Oct;13(10):685-700. doi: 10.1038/nrc3580. Review. Erratum in: Nat Rev Cancer. 2013 Nov;13(11):820.

PMID:
24060861
13.

Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.

Sattu K, Hochgräfe F, Wu J, Umapathy G, Schönherr C, Ruuth K, Chand D, Witek B, Fuchs J, Li PK, Hugosson F, Daly RJ, Palmer RH, Hallberg B.

FEBS J. 2013 Nov;280(21):5269-82. doi: 10.1111/febs.12453. Epub 2013 Aug 22.

14.

Jeb/Alk signalling regulates the Lame duck GLI family transcription factor in the Drosophila visceral mesoderm.

Popichenko D, Hugosson F, Sjögren C, Dogru M, Yamazaki Y, Wolfstetter G, Schönherr C, Fallah M, Hallberg B, Nguyen H, Palmer RH.

Development. 2013 Aug;140(15):3156-66. doi: 10.1242/dev.094466. Epub 2013 Jul 3.

15.

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.

Chand D, Yamazaki Y, Ruuth K, Schönherr C, Martinsson T, Kogner P, Attiyeh EF, Maris J, Morozova O, Marra MA, Ohira M, Nakagawara A, Sandström PE, Palmer RH, Hallberg B.

Dis Model Mech. 2013 Mar;6(2):373-82. doi: 10.1242/dmm.010348. Epub 2012 Oct 25.

16.

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RE.

Cancer Cell. 2012 Jul 10;22(1):117-30. doi: 10.1016/j.ccr.2012.06.001.

17.

Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment.

Mazot P, Cazes A, Dingli F, Degoutin J, Irinopoulou T, Boutterin MC, Lombard B, Loew D, Hallberg B, Palmer RH, Delattre O, Janoueix-Lerosey I, Vigny M.

PLoS One. 2012;7(3):e33581. doi: 10.1371/journal.pone.0033581. Epub 2012 Mar 30.

18.

Anaplastic lymphoma kinase in human cancer.

Schonherr C, Hallberg B, Palmer R.

Crit Rev Oncog. 2012;17(2):123-43. Review.

PMID:
22471704
19.

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.

Schönherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V, Djos A, Martinsson T, Christensen JG, Palmer RH, Hallberg B.

Oncogene. 2012 Dec 13;31(50):5193-200. doi: 10.1038/onc.2012.12. Epub 2012 Jan 30.

PMID:
22286764
20.

ALK and NSCLC: Targeted therapy with ALK inhibitors.

Hallberg B, Palmer RH.

F1000 Med Rep. 2011;3:21. doi: 10.3410/M3-21. Epub 2011 Nov 1.

Supplemental Content

Loading ...
Support Center